The impact of micronized progesterone on breast cancer risk: a systematic review.

Stute, Petra; Wildt, L; Neulen, J (2018). The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric, 21(2), pp. 111-122. Informa Healthcare 10.1080/13697137.2017.1421925

[img]
Preview
Text
29384406.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview

Postmenopausal women with an intact uterus using estrogen therapy should receive a progestogen for endometrial protection. The debate on bioidentical hormones including micronized progesterone has increased in recent years. Based on a systematic literature review on the impact of menopausal hormone therapy (MHT) containing micronized progesterone on the mammary gland, an international expert panel's recommendations are as follows: (1) estrogens combined with oral (approved) or vaginal (off-label use) micronized progesterone do not increase breast cancer risk for up to 5 years of treatment duration; (2) there is limited evidence that estrogens combined with oral micronized progesterone applied for more than 5 years are associated with an increased breast cancer risk; and (3) counseling on combined MHT should cover breast cancer risk - regardless of the progestogen chosen. Yet, women should also be counseled on other modifiable and non-modifiable breast cancer risk factors in order to balance the impact of combined MHT on the breast.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Gynaecology

UniBE Contributor:

Stute, Petra

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1369-7137

Publisher:

Informa Healthcare

Language:

English

Submitter:

Monika Zehr

Date Deposited:

13 Mar 2019 13:14

Last Modified:

13 Mar 2019 13:14

Publisher DOI:

10.1080/13697137.2017.1421925

PubMed ID:

29384406

Uncontrolled Keywords:

Micronized progesterone breast biopsy breast cancer risk breast density combined estrogen–progestogen therapy hormone therapy menopause

BORIS DOI:

10.7892/boris.125894

URI:

https://boris.unibe.ch/id/eprint/125894

Actions (login required)

Edit item Edit item
Provide Feedback